ABL1 and precursor B-cell acute lymphoblastic leukemia: This idea is supported by the finding that inhibition of HO-1 induces apoptosis in BCR-ABL-positive B-ALL (acute lympohoblastic leukemia) and increases the sensitivity to treatment by imatinib [34].